These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 15163466)

  • 1. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
    Brites FD; Verona J; Schreier LE; Fruchart JC; Castro GR; Wikinski RL
    Arch Med Res; 2004; 35(3):235-40. PubMed ID: 15163466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated HDL2-paraoxonase and reduced CETP activity are associated with a dramatically lower ratio of LDL-cholesterol/total cholesterol in a hypercholesterolemic and hypertriglyceridemic patient.
    Lee JH; Park JH; Lee SH; Kim JR; Cho KH
    Int J Mol Med; 2010 Jun; 25(6):945-51. PubMed ID: 20428800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.
    Rizos E; Tambaki AP; Gazi I; Tselepis AD; Elisaf M
    Prostaglandins Leukot Essent Fatty Acids; 2005 Mar; 72(3):203-9. PubMed ID: 15664305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDL metabolic activities in a boy with lipoprotein lipase deficiency and his family.
    Brites F; Verona J; Fernández K; Henriksen F; Fruchart J; Cesar M; Castro G; Wikinski R
    Eur J Clin Invest; 2004 Jul; 34(7):467-74. PubMed ID: 15255783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
    Dirican M; Akca R; Sarandol E; Dilek K
    J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
    Noto H; Hara M; Karasawa K; Iso-O N; Satoh H; Togo M; Hashimoto Y; Yamada Y; Kosaka T; Kawamura M; Kimura S; Tsukamoto K
    Arterioscler Thromb Vasc Biol; 2003 May; 23(5):829-35. PubMed ID: 12649088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.
    Milionis HJ; Tambaki AP; Kanioglou CN; Elisaf MS; Tselepis AD; Tsatsoulis A
    Thyroid; 2005 May; 15(5):455-60. PubMed ID: 15929667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
    Liberopoulos EN; Papavasiliou E; Miltiadous GA; Cariolou M; Siamopoulos KC; Tselepis AD; Elisaf MS
    Perit Dial Int; 2004; 24(6):580-9. PubMed ID: 15559488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
    Papavasiliou EC; Gouva C; Siamopoulos KC; Tselepis AD
    Nephrol Dial Transplant; 2006 May; 21(5):1270-7. PubMed ID: 16421163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H; Pahl MV; Elahimehr R; Vaziri ND
    Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties.
    Kontush A; de Faria EC; Chantepie S; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):526-33. PubMed ID: 14739123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
    Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL capacity to inhibit LDL oxidation in well-trained triathletes.
    Brites F; Zago V; Verona J; Muzzio ML; Wikinski R; Schreier L
    Life Sci; 2006 May; 78(26):3074-81. PubMed ID: 16488445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of beta-thalassemia/hemoglobin E patients.
    Phumala Morales N; Cherlermchoung C; Fucharoen S; Chantharaksri U
    Clin Chem Lab Med; 2007; 45(7):884-9. PubMed ID: 17617032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes.
    Gomes MB; Cobas RA; Nunes E; Nery M; Castro-Faria-Neto HC; Tibiriçá E
    Prostaglandins Other Lipid Mediat; 2008 Dec; 87(1-4):42-6. PubMed ID: 18718550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
    Rosenblat M; Karry R; Aviram M
    Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
    Tsimihodimos V; Karabina SA; Tambaki AP; Bairaktari E; Goudevenos JA; Chapman MJ; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):306-11. PubMed ID: 11834533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid.
    Kujiraoka T; Hattori H; Ito M; Nanjee MN; Ishihara M; Nagano M; Iwasaki T; Cooke CJ; Olszewski WL; Stepanova IP; Egashira T; Miller NE
    Atherosclerosis; 2004 Sep; 176(1):57-62. PubMed ID: 15306175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite.
    Connelly PW; Draganov D; Maguire GF
    Free Radic Biol Med; 2005 Jan; 38(2):164-74. PubMed ID: 15607900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.